Merz Aesthetics

Merz Aesthetics is the dedicated aesthetics division of Merz Pharmaceuticals, a family-owned German healthcare company with roots stretching back to 1908. Where many aesthetics companies are relatively young, Merz brings more than a century of pharmaceutical heritage to a sector it has helped define.

The division focuses exclusively on medical aesthetics, offering a portfolio spanning neurotoxins, dermal fillers, and energy-based device technologies. Its neurotoxin brand Xeomin (incobotulinumtoxinA) is approved in multiple markets for both aesthetic and therapeutic indications, and is notable for its purified formulation, which contains no complexing proteins. The Belotero range of hyaluronic acid fillers addresses a broad spectrum of facial rejuvenation needs, from fine lines to volumisation.

Merz Aesthetics operates globally, with a significant commercial presence across North America, Europe, and Asia-Pacific. The division is headquartered in Raleigh, North Carolina, reflecting the strategic importance of the United States as its largest aesthetics market, while its parent company remains based in Frankfurt, Germany.

Beyond injectables, the company has expanded into energy-based devices through partnerships and acquisitions, broadening its offering to aesthetic practitioners who seek a more comprehensive treatment portfolio. Its education and training programmes for healthcare professionals are a recognised part of its commercial model, supporting clinical best practice alongside product adoption.

As a privately held entity within the Merz family group, the division is not publicly listed, allowing a longer-term investment horizon than many listed peers. This structure has supported sustained investment in clinical evidence and product development across its core categories.

Further information is available at merzaesthetics.com.